Doctor of Osteopathy Program year 2023 Reported 2019–2023 Source: CMS Open Payments, 2026 publication

Kirk Kinard

Interventional Pain Medicine Oxford, MS Doctor of Osteopathy

NPI 1376740803 CMS profile 17487

2215 Jefferson Davis Dr, Oxford, MS 38655

Open in the dashboard

General payments

$1,560

84 records reported · program years 2019–2023

Research payments

$0

Paid to them · None reported · program years 2019–2023

Ownership & investment interest

$0

None reported

Through program year 2023, Kirk Kinard of Oxford, MS is reported in the CMS Open Payments database as having received $1,560 across 84 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 31st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2023 General $217 12
2022 General $579 31
2021 General $422 17
2020 General $74 4
2019 General $268 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kirk Kinard
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Kirk Kinard were reported at $0. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Kirk Kinard Interventional Pain Medicine median Middle half National median
2019 $268 $684 $216–$2,079 $163
2020 $74 $382 $122–$1,109 $114
2021 $422 $552 $167–$1,554 $132
2022 $579 $605 $187–$1,924 $149
2023 $217 $671 $195–$1,915 $160
2024 $0 $684 $206–$1,837 $164
2025 $0 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2023
  1. Boston Scientific Corporation $250 15 payments
  2. Collegium Pharmaceutical, Inc. $233 15 payments
  3. Nevro Corp. $230 16 payments
  4. Scilex Pharmaceuticals Inc. $188 11 payments
  5. Epimed International, Inc $134 1 payment
  6. SI-BONE, Inc. $103 5 payments
  7. Nalu Medical, Inc. $99 4 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $95 5 payments
  9. Indivior Inc. $65 4 payments
  10. Kowa Pharmaceuticals America, Inc. $46 2 payments
  11. Other $118 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2023
  1. Food and Beverage $1,560 84 payments
Products named General payments · program years 2019–2023
  1. XTAMPZA $181 12 payments
  2. ZTLido $145 8 payments
  3. WaveWriter Alpha Prime 16 $142 8 payments
  4. Catheters and Needles $134 1 payment
  5. Senza Spinal Cord Stimulation System $131 11 payments
  6. Nalu Neurostimulation System $99 4 payments
  7. RELISTOR $95 5 payments
  8. IFUSE IMPLANT $84 4 payments
  9. SUBLOCADE $65 4 payments
  10. Omnia $63 3 payments
  11. Other $454 26 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

84 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2023

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record